MREO: Class Action Filed—Investors Urged to Act Now!

Background: Trial Failure Sparks Class Action

Mereo BioPharma Group plc (NASDAQ: MREO) – a UK-based rare disease biotech – faces a shareholder class action lawsuit after a dramatic collapse in its stock price. The lawsuit covers investors who bought MREO shares from June 5, 2023, through December 26, 2025, and alleges that the company misled investors with overly positive statements about its lead drug’s Phase 3 trials (intellectia.ai). On December 29, 2025, Mereo disclosed that neither of its Phase 3 studies (ORBIT and COSMIC, evaluating the antibody setrusumab for brittle bone disease) met their primary endpoints of reducing fracture rates (www.sec.gov). This revelation caused Mereo’s American Depository Share (ADS) price to plunge from $2.31 (just before the news) to $0.29 – an 87.7% collapse that wiped out a large portion of shareholder value (intellectia.ai). Multiple law firms (Portnoy, Robbins LLP, Gross Law, etc.) have since invited investors to seek lead-plaintiff status by the April 6, 2026 deadline (intellectia.ai) (intellectia.ai). The class action is a new overhang on MREO, compounding the challenges from its failed trial outcome.

Dividend Policy and Yield

Mereo has never paid a dividend, consistent with its profile as a clinical-stage biotech with ongoing losses. In fact, the company explicitly states it “has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any… in the foreseeable future,” opting to reinvest any funds into drug development (www.sec.gov). Consequently, MREO’s dividend yield is 0%, and traditional income metrics like AFFO/FFO do not apply. Investors seeking returns here are relying entirely on capital appreciation potential, not dividend income. Mereo’s focus on R&D and the absence of positive earnings mean that typical REIT-like cash flow metrics (Funds From Operations, etc.) are not reported – the company has no operating cash flows from product sales to support any payouts (www.sec.gov). This policy is common for pre-revenue biotech firms and is unlikely to change until Mereo achieves sustainable profitability (which remains uncertain).

Leverage and Debt Maturities

Mereo’s balance sheet carries minimal debt following recent conversions of its outstanding notes. Notably, in February 2025 the company’s remaining £3.8 million convertible Novartis Loan Note (a note held by Novartis from a prior asset deal) was fully converted into equity (www.sec.gov) (www.sec.gov). As a result, MREO now has no significant interest-bearing liabilities on its books (www.sec.gov). Prior to conversion, the Novartis note bore a 9% interest rate and was due to mature around early 2025 (www.sec.gov) – but that obligation effectively disappeared with the conversion into shares. Other than typical short-term payables and lease liabilities, Mereo currently has no bank loans or bond debt. This means no looming debt maturities threaten the company’s near-term viability; it won’t be forced into refinancing under adverse conditions. The lack of leverage gives Mereo some financial flexibility – however, it also means the company relies heavily on equity financing and partnerships to fund operations (since it has no revenue and limited debt capacity). With ~$48.7 million in cash remaining as of Q3 2025 (www.sec.gov), Mereo has indicated its resources could last into 2027 under a sharply reduced spending plan (www.sec.gov). Still, any major new trials or commercialization efforts would require new funding, likely through dilutive stock offerings or partner capital infusions.

Coverage and Cash Flow Considerations

Traditional coverage ratios (such as interest coverage or payout coverage) are largely irrelevant for Mereo at this stage. With effectively no debt interest to service and no dividends to cover, MREO’s “coverage” is more about its cash burn versus cash on hand. The company has historically run at a net loss (accumulated deficit was $486.6 million as of mid-2025) and will continue to incur losses for the foreseeable future (www.sec.gov). The key coverage concern for investors is whether Mereo’s cash reserves can cover its R&D and operating expenses until value-creating milestones occur. Management has already taken steps to cut expenditures – for example, reducing pre-commercial and manufacturing activities after the trial failure (www.sec.gov). If we consider cash coverage: at the current burn rate, the ~$48 million cash pile (Q3 2025) might sustain operations for roughly 18–24 months, extended by recent cost cuts (www.sec.gov) (www.sec.gov). However, to complete Phase 3 development of its drugs or reach commercialization, Mereo will need to secure additional capital. The company acknowledges this funding need, stating that it will pursue “non-dilutive funding, public or private equity or debt financing or other sources” to execute its plans (www.sec.gov). In summary, while near-term liquidity is adequate under slimmed-down budgets, Mereo’s long-term cash coverage is deficient without external infusions – a critical aspect for investors to monitor.

Valuation and Outlook

After the steep selloff, MREO’s equity valuation has been crushed. At around $0.40 per ADS (as of early 2026), the market capitalization – roughly $50–60 million – is barely above the company’s cash on hand (www.sec.gov). In other words, the market is assigning very little value to Mereo’s drug pipeline and intellectual property at present. This depressed valuation reflects extreme investor skepticism following the Phase 3 failure. Notably, Mereo now trades near its book value (shareholders’ equity was ~$54 million mid-2025) (www.sec.gov), implying that the stock is valued almost like a cash shell. By comparison, prior to the trial result, MREO’s market cap was near $350 million, suggesting that nearly all the expected value from setrusumab has evaporated. Price-to-earnings (P/E) is not meaningful here due to negative earnings, and even price-to-book (P/B) is ~1x, unusually low for a biotech with ongoing programs. Some Wall Street analysts still see potential upside – for example, the consensus 12-month price target was about $2.08 (average) even after the crash (intellectia.ai). Cantor Fitzgerald, while cutting its target in half post-data, maintained an Overweight rating with a $3 target (vs. ~$6 prior) (intellectia.ai). These targets suggest a speculative view that Mereo’s remaining assets or new analyses could yield a turnaround. However, achieving such upside hinges on clearing major uncertainties: finding a path forward for setrusumab or a partner for its other drug. In the absence of positive catalysts, MREO’s current valuation essentially prices in continued distress. The stock’s low price also creates mechanical risks (e.g. potential Nasdaq non-compliance if shares stay under $1, which could force a reverse split). Overall, MREO can be seen as a high-risk, binary situation – trading at “option value” levels – where any future success in the pipeline could result in outsized gains, but failure or inaction could mean further stagnation or dilution at these low levels.

Key Risks Facing Investors

Investing in MREO carries significant risks, both fundamental and event-driven:

– Pipeline Failure & Efficacy Risk: The foremost risk is that Mereo’s leading drug setrusumab may ultimately prove unviable. The Phase 3 ORBIT and COSMIC trials failing to meet fracture-rate endpoints is a severe blow (www.sec.gov). While bone density improved, regulators prioritize fracture reduction – without which approval is unlikely. There’s a risk that no clear remediation (such as another trial or subset analysis) will rescue the program, effectively leaving the company without its flagship product. Mereo’s other pipeline candidate, alvelestat for alpha-1 antitrypsin deficiency, is still unproven at Phase 2. Any setback in its development or inability to show clinical benefit would compound the company’s troubles.

– Funding & Dilution Risk: Mereo will need substantial financing to continue R&D or to commercialize a drug. The company has no revenue and is chronically unprofitable (www.sec.gov). Even after deep cost cuts, current cash will only last a couple of years (www.sec.gov). A large equity raise at today’s depressed stock price would be highly dilutive to existing shareholders. Alternatively, taking on debt or convertibles (if available at all) could burden the company financially. The timing of any needed capital raise is a risk – if delayed too long, Mereo’s negotiating position worsens; if done too early/cheaply, it locks in massive dilution.

– Regulatory and Development Risk: Drug development in rare diseases faces regulatory uncertainties. It’s possible the FDA or EMA could require additional or different trials for setrusumab given the Phase 3 outcomes. Even for alvelestat, regulators have guided a single Phase 3 with novel endpoints (www.globenewswire.com) (www.globenewswire.com), but success isn’t guaranteed. Any stricter regulatory demands could increase costs and delays. There is also risk around attracting a partner for alvelestat – a partnership is crucial to fund its Phase 3, and failure to secure one would stall the program.

– Legal and Reputation Risk: The current class action lawsuit itself could pose some financial and reputational risk. While such securities lawsuits often get covered by D&O insurance or settle for modest sums, they can distract management and tarnish the company’s credibility. The complaint’s core allegation – that management misled investors about trial prospects (intellectia.ai) – raises a red flag on transparency. If evidence emerges of intentional misrepresentation, it could damage trust with investors or bring SEC scrutiny. Even absent a court finding, Mereo’s management now has to overcome a credibility deficit.

– Market & Trading Risks: With MREO stock now under $1, there’s a risk of Nasdaq delisting if the price doesn’t recover. This could reduce liquidity and force some funds to sell. The stock’s low price also makes it volatile (small absolute moves equate to large percentages) and potentially subject to speculative trading swings. Investor sentiment is poor post-drop, so negative news (or lack of progress) could lead to further declines. Broader market conditions for biotech (risk appetite, funding environment) also influence MREO – e.g. if biotech funding tightens, Mereo’s ability to raise capital or strike deals could worsen.

Red Flags and Governance Issues

In addition to the risks above, Mereo’s recent history reveals some red flags in governance and execution:

– Overly Optimistic Guidance: The class action highlights that Mereo’s public communications were overly rosy about setrusumab’s outlook (intellectia.ai). Prior to the Phase 3 readout, management emphasized interim data showing reduced fractures and strong bone density gains (ir.ultragenyx.com) (ir.ultragenyx.com). These statements, while factually based on Phase 2 subset results, may have set unrealistic expectations. Investors are now questioning whether management downplayed the uncertainty around achieving the hard endpoint (fracture reduction). This episode raises concerns about how forthcoming management is with bad news and risk factors.

– Shareholder Activism: In late 2022, Mereo’s largest shareholder – Rubric Capital (a hedge fund) – engaged in a public battle with the company’s board and management. Rubric accused the board of failing to consider strategic alternatives and demanded changes (www.fiercebiotech.com) (www.fiercebiotech.com). The conflict ended with Mereo signing a truce and giving Rubric four seats on the board (www.fiercebiotech.com). Such a significant board overhaul suggests that independent investors had serious concerns with the prior direction of the company. It’s a red flag when a biotech’s owners feel the need to intervene so forcefully – indicating potential past missteps in capital allocation or strategy. While the new board members may bring fresh oversight, the situation underscores governance instability.

– Frequent Strategic Shifts: Mereo has a complex lineage – it acquired assets from Novartis and AstraZeneca, merged with OncoMed Therapeutics in 2019, and pivoted to focus on rare diseases. This history means the company’s pipeline is a patchwork of in-licensed or merged programs. There have been signs of strategy drift, from oncology assets (e.g. an anti-TIGIT antibody) to rare pediatric diseases. For example, one oncology candidate (navicixizumab) was out-licensed, and management now concentrates on the two rare disease drugs (www.fiercebiotech.com). While portfolio pruning can be positive, the past frequent shifts might indicate that earlier programs did not pan out as hoped. Investors may view Mereo’s story as a series of pivots, which can be a red flag about the inherent quality of the pipeline or the focus of management.

– Insider and Partner Dynamics: Another point to watch is the relationship with partners like Ultragenyx. Ultragenyx paid Mereo $50 million in 2020 for rights to setrusumab outside Europe (www.fiercebiotech.com), showing strong interest. If Ultragenyx now walks away or deprioritizes setrusumab after the failed endpoints, that is a negative signal. Conversely, if Ultragenyx continues to collaborate (perhaps on re-analyzing data or considering a pediatric path), it could lend credibility. The absence of any reassuring statement from Ultragenyx post-failure could be interpreted bearishly. Similarly, insiders’ actions are telling: any significant insider stock sales before the December 2025 announcement would be a glaring red flag (none have been reported so far). Going forward, insider buying or selling activity will be closely scrutinized as a gauge of management’s own confidence in a turnaround.

In summary, the combination of a shareholder lawsuit, prior activist intervention, and a major trial failure paints a picture of a company with elevated governance risk. Mereo’s leadership will need to demonstrate improved transparency and execution to rebuild investor confidence.

Open Questions and What to Watch

1. Can Setrusumab Be Salvaged? Mereo’s management expressed disappointment but hinted at possible next steps for setrusumab, “especially in pediatrics given the totality of the data and lack of other treatment options” (www.sec.gov). An open question is whether a subset of patients (e.g. young children in the COSMIC study) showed any trend toward fewer fractures, or if longer follow-up might reveal a benefit. Will the company (and Ultragenyx) design a new trial or seek regulatory advice on using bone mineral density (BMD) as a surrogate endpoint? Or is setrusumab essentially a failed asset? Investors should watch for any detailed data analyses from ORBIT/COSMIC – for example, fracture outcomes by patient subgroups or hints that the drug needs more time to show effect. The fate of setrusumab is critical: if no viable path forward emerges, Mereo loses its lead program and the justification for Ultragenyx’s partnership.

2. Will Mereo Secure a Partner (or Buyer) for Alvelestat? Alvelestat (for alpha-1 antitrypsin deficiency lung disease) is now the company’s most promising asset. Regulators have agreed on a Phase 3 design (www.globenewswire.com), and importantly, no confirmatory second trial is required if that Phase 3 meets its endpoints (www.globenewswire.com). However, Mereo has made clear it does not intend to fund this Phase 3 alone – it has been actively seeking a partnership to finance and co-develop alvelestat (www.globenewswire.com) (www.globenewswire.com). The big question: can they strike a partnership deal in 2026? Potential partners will evaluate alvelestat’s Phase 2 data (which showed some positive biomarker and lung function signals) and the market opportunity in AATD, which is a rare condition. If a deal materializes, on what terms? A strong partnership (with upfront cash and shared costs) could significantly de-risk Mereo’s future. Conversely, failure to find a partner would force Mereo into a tough spot – either shelve alvelestat, attempt a dilutive raise to fund the trial internally, or perhaps sell the asset outright. Also, given Mereo’s low valuation, a strategic acquirer might consider buying the whole company to obtain alvelestat (and other assets) on the cheap. Investors should keep an eye on any rumors or announcements regarding partnership negotiations in coming quarters.

3. How Will the Class Action Resolve? While the shareholder lawsuit is a secondary concern to fundamentals, it does raise the issue of potential financial or managerial consequences. Will Mereo settle the case quickly (perhaps after the lead plaintiff is appointed), or fight it in court? Any settlement likely would be covered by insurance, but if the lawsuit uncovers troubling internal communications (for example, proof that executives knew the trials were likely failures while talking up the stock), it could hasten management changes or further activism. The lead plaintiff deadline (April 6, 2026) is an interim milestone (intellectia.ai); after that, we’ll learn more about the plaintiffs’ claims. It’s worth watching if major institutional investors join the suit or if the case affects Mereo’s reputation with regulators and partners. This open question ties into broader concerns about leadership credibility. New board members installed by Rubric in 2022 might push for more accountability if the lawsuit’s allegations gain traction.

4. Can Mereo Rebuild Investor Confidence (or Is a Drastic Move Coming)? With its share price in the pennies and its flagship drug floundering, Mereo’s management is at a crossroads. Will they opt for restructuring or strategic alternatives? One path could be doubling down on the rare disease focus – cut all other projects, minimize cash burn, and try to advance alvelestat with a partner while salvaging what’s possible with setrusumab. Another path might be exploring a merger or sale: for instance, merging with another rare disease biotech to achieve scale, or selling Mereo’s remaining assets to a bigger player (potentially Ultragenyx or a respiratory-focused company for alvelestat). Given Rubric Capital’s activist involvement, it would not be surprising if pressure for strategic transactions resurfaces now that the stock is so low. On the other hand, insiders might believe the market is undervaluing the company’s prospects – any insider buy-in (literally, via share purchases) would be a positive signal. In the coming months, look for updates at investor conferences, any small acquisitions or disposals of pipeline assets, and how management communicates its plan. The clarity (or lack thereof) in Mereo’s strategy will be a key determinant of whether investors give the company another chance or continue to abandon ship.

5. How Does the Ultragenyx Collaboration Evolve? Finally, a crucial open question is what Ultragenyx Pharmaceutical (Mereo’s development partner on setrusumab) decides to do. Ultragenyx has been co-funding and running these OI trials; the setback is a blow to their pipeline as well. If Ultragenyx remains engaged, it might signal some residual hope for setrusumab – for example, they might present data at a scientific meeting or discuss next steps publicly. If instead Ultragenyx quietly pulls back (or if Mereo announces the partnership has been restructured or terminated), that will speak volumes about the drug’s prospects. Additionally, does Ultragenyx show interest in Mereo’s other assets? Thus far, the partnership is specific to setrusumab. Investors will want to see whether Ultragenyx writes off the program, or whether – given the lack of alternative treatments for osteogenesis imperfecta – they push for a way to repurpose the strong BMD gains observed (perhaps via an extended trial or different patient subgroup). The answer to this will influence Mereo’s strategy: a supportive partner might help fund any further work, whereas an exit by Ultragenyx could leave Mereo fully on its own. Any public commentary from Ultragenyx or joint statements will be telling.

In summary, Mereo BioPharma is at a critical juncture. The class action and stock crash underscore past disappointments, but the company still holds assets that could create future value if handled adeptly. Investors are urged to stay vigilant – now is the time to scrutinize MREO’s moves, as outcomes in the coming year (lawsuit developments, partnership news, and strategic decisions) will determine whether this deeply discounted stock marks a turnaround story or a cautionary tale.

Sources: Key information in this report is derived from Mereo’s SEC filings, official press releases, and reputable financial news. These include the company’s 20-F annual report (www.sec.gov), recent 10-Q quarterly filings (www.sec.gov) (www.sec.gov), and Mereo’s December 29, 2025 press release on the ORBIT/COSMIC trial results (www.sec.gov) (www.sec.gov). Developments regarding the class action lawsuit and stock drop are documented in GlobeNewswire notices and analysis pieces (intellectia.ai) (intellectia.ai). Industry commentary, such as FierceBiotech’s coverage of the 2022 Rubric Capital activist campaign (www.fiercebiotech.com), provides context on governance changes. Investors should review these source materials (and any updates thereto) for a full understanding of MREO’s situation and conduct their own due diligence when considering action. The evolving nature of clinical data and legal proceedings means new information could alter the risk profile rapidly. Stay tuned to official filings and news as this story unfolds.

For informational purposes only; not investment advice.